A Period Seroprevalence(SARS-CoV-2) Survey in MHCCN Cancer Healthcare Workers (HCWs) Providing Patient Care during the Height of the Outbreak: A Registry Study (Second Year Progress)
Download Full Text (608 KB)
In December 2019, emergence of a new coronavirus in Wuhan, China heralded the onset of a global pandemic (aka Covid-19) that is well into its third year. At the outset, the initial first wave of the alpha variant in 2020 had less impact on our state and HCWs. In December 2020, Covid-19 vaccinations became available. By fall and winter 2021-2022, the delta and subsequent omicron variants nearly overwhelmed Maine healthcare systems and work force. In June 2020, we embarked on a period seroprevalencestudy in the MaineHealthCancer Network (MHCCN) to document Covid-19 exposure in our rural cancer care workforce. Enrollment continues over two discrete periods during our study, essentially pre-and post-vaccination and with two discrete SARS-CoV-2 antibody-testing platforms as the pandemic evolved. This ongoing study provides additional insight into viral antibody (Ab) response across the settings of potential occupational exposure, rapid community spread, and vaccination.
Knight, Caroline; Prescott, Jill; Hobart, Jill; Saunders, Jamie; Caron, Kimberly; Neptune, Sandra; Brown, Patty; Sturtevant, Kyla; Eller, Sean; Lemire, Lisa; Breggia, Anne; Guerin-Staples, Susan L.; Lucas, Lee; Han, Paul; Kumar, Rachit; Liu, Johnson; Carlson, Robert; and Remick, Scot, "A Period Seroprevalence(SARS-CoV-2) Survey in MHCCN Cancer Healthcare Workers (HCWs) Providing Patient Care during the Height of the Outbreak: A Registry Study (Second Year Progress)" (2022). Costas T. Lambrew Research Retreat 2022. 37.
2022 Lambrew Retreat